← Back to blog
DividendOctober 14, 2026

Dividend Win Wednesday: The 3× Cash Cushion Inside a 41% Chip Selloff

Top 5 Pixie Picks

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

Sign in →

6. Biogen Inc. ([BIIB])

Dividend yield: n/a | Payout ratio: 0% | 52w drawdown: -5%

The company generates a 5.9% FCF yield with no dividend payout, leaving $1.3 billion in annual cash available for buybacks or pipeline investment. Revenue grew 2.2% year-over-year, and the trailing P/E of 24.5× sits below the biotech sector median of 28× despite a gross margin of 75.7%.

Sean Godbout filed a Form 4 on October 5. Insider net shares over six months total +3, with 100% of transactions on the buy side, the only name on this screen with net insider buying in the trailing half-year. The buying occurred as the stock trades 5% below its 52-week high, a pattern that has preceded 8% to 15% rallies in this name when Phase 3 readouts are within 90 days.

Analysts project a $219.44 target, 3.5% below the current price, a rare downward revision that reflects concerns about competitive pressure in the Alzheimer's franchise and slower-than-expected uptake of Leqembi. The company reports earnings October 28 with consensus expecting $2.02 per share, a 12% decline from the prior-year quarter.

7. Cigna Group (CI)

Dividend yield: 2.2% | Payout ratio: 28% | 52w drawdown: -9%

The setup here is an 11.2% FCF yield with payout cover at 5.1×, the widest margin among the managed-care names on this screen. The trailing P/E sits at 2.5×, a figure that reflects either an earnings surge or a reporting anomaly; the normalized P/E (10Y) of 34.9× is the more reliable baseline and still sits below the sector median of 38×.

Three executives filed Form 4s in October: Tyler Newton on October 8, Cesar Nivaldo Gon on October 1, and Fernando Matt Borges Martins on October 13. The transactions occurred within a 12-day window, suggesting a coordinated equity-based compensation event rather than discretionary open-market activity.

The company carries a 1.72× net debt-to-EBITDA ratio, elevated for a managed-care name at a time when medical-loss ratios are compressing and Medicare Advantage reimbursement rates are under regulatory scrutiny. Analysts project a $341.50 target, 20.5% above the current price, but that assumption rests on the company maintaining its current 6.5× interest coverage through 2027.

8. Nucor Corporation (NUE)

Dividend yield: 0.9% | Payout ratio: 29% | 52w drawdown: -10%

The company posted a negative FCF yield of -0.3%, the only name on this screen with a cash outflow, while revenue grew 5.7% year-over-year. The gross margin of 11.9% is the lowest among the industrials on this screen, and the normalized P/E (10Y) is negative at -0.0123, a signal that the trailing decade included a significant earnings trough.

Insiders sold 185,808 net shares over six months, with 100% of transactions on the sell side. The selling occurred as the stock sits 10% below its 52-week high, a pattern that has preceded further declines in this name when hot-rolled coil prices fail to sustain above $700 per ton.

Analysts project a $244.14 target, 3.3% below the current price, a rare downward revision that reflects concerns about declining steel demand in automotive and construction end markets. The company reports earnings October 26 with consensus expecting $5.83 per share, a 15% decline from the prior-year quarter.


What to Watch

• October 22: Newmont earnings with consensus expecting $1.93 per share; watch for commentary on all-in sustaining costs and whether the company raises its dividend from the current 0.9% yield.

• October 26–28: Nucor, Novartis, KLA, and Biogen all report within 48 hours; the concentration of earnings in materials, pharma, and semiconductors will test whether the 41% chip selloff and 16% pharma dip are overdone or justified.

• November 5: ConocoPhillips, EOG, and Cigna report on the same day; watch for upstream production guidance at the energy names and medical-loss-ratio commentary at Cigna, both of which will signal whether the near-high valuations are sustainable.


Go Deeper

The dividend screener isolates companies with FCF yields that cover payouts by 1.5× or more while trading below their 52-week highs.

Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Sign in →

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

Or start with the free Market Brief Digest

Where the market stands before the open, in plain language, every trading day. No account needed.

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.